Log in

Alector Stock Forecast, Price & News

-0.03 (-0.21 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $14.07
50-Day Range
MA: $13.56
52-Week Range
Now: $14.07
Volume5.28 million shs
Average Volume564,294 shs
Market Capitalization$1.12 billion
P/E RatioN/A
Dividend YieldN/A
Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:ALEC



Sales & Book Value

Annual Sales$21.22 million
Book Value$2.83 per share


Net Income$-105,390,000.00
Net Margins-775.34%


Market Cap$1.12 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
-0.03 (-0.21 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALEC News and Ratings via Email

Sign-up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Alector (NASDAQ:ALEC) Frequently Asked Questions

How has Alector's stock price been impacted by Coronavirus?

Alector's stock was trading at $24.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALEC shares have decreased by 43.5% and is now trading at $14.07.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Alector?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Alector

When is Alector's next earnings date?

Alector is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Alector

How were Alector's earnings last quarter?

Alector Inc (NASDAQ:ALEC) announced its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.09. Alector had a negative net margin of 775.34% and a negative return on equity of 50.88%.
View Alector's earnings history

What price target have analysts set for ALEC?

8 brokers have issued 1 year price targets for Alector's stock. Their forecasts range from $28.00 to $41.00. On average, they expect Alector's stock price to reach $32.80 in the next twelve months. This suggests a possible upside of 133.1% from the stock's current price.
View analysts' price targets for Alector

Are investors shorting Alector?

Alector saw a increase in short interest in August. As of August 14th, there was short interest totaling 8,750,000 shares, an increase of 20.9% from the July 30th total of 7,240,000 shares. Based on an average daily volume of 895,600 shares, the short-interest ratio is presently 9.8 days. Approximately 16.7% of the company's shares are sold short.
View Alector's Short Interest

Who are some of Alector's key competitors?

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), Pfizer (PFE), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Gossamer Bio (GOSS), NVIDIA (NVDA), Intel (INTC), AbbVie (ABBV), Advanced Micro Devices (AMD) and Crispr Therapeutics (CRSP).

Who are Alector's key executives?

Alector's management team includes the following people:
  • Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)
  • Dr. Arnon Rosenthal, Co-Founder, CEO, Pres & Director (Age 64)
  • Dr. Robert Paul M.D., Ph.D., Chief Medical Officer (Age 51)
  • Dr. Robert S. King, Chief Devel. Officer (Age 56)
  • Dr. Asa Abeliovich M.D., Ph.D., Co-Founder

When did Alector IPO?

(ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

What is Alector's stock symbol?

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Who are Alector's major shareholders?

Alector's stock is owned by a variety of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (7.54%), Vanguard Group Inc. (6.14%), Federated Hermes Inc. (5.40%), FMR LLC (4.39%), Gilder Gagnon Howe & Co. LLC (3.24%) and Deerfield Management Company L.P. Series C (2.12%). Company insiders that own Alector stock include Calvin Yu, David M Wehner, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney and Terrance Mcguire.
View institutional ownership trends for Alector

Which institutional investors are selling Alector stock?

ALEC stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Marshall Wace North America L.P., Gilder Gagnon Howe & Co. LLC, Federated Hermes Inc., FMR LLC, Deerfield Management Company L.P. Series C, Holocene Advisors LP, and Artal Group S.A.. Company insiders that have sold Alector company stock in the last year include Calvin Yu, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney, and Terrance Mcguire.
View insider buying and selling activity for Alector

Which institutional investors are buying Alector stock?

ALEC stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Vanguard Group Inc., Point72 Asset Management L.P., Man Group plc, Swiss National Bank, Marshall Wace LLP, Nuveen Asset Management LLC, and First Trust Advisors LP. Company insiders that have bought Alector stock in the last two years include David M Wehner, and Orbimed Advisors Llc.
View insider buying and selling activity for Alector

How do I buy shares of Alector?

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alector's stock price today?

One share of ALEC stock can currently be purchased for approximately $14.07.

How big of a company is Alector?

Alector has a market capitalization of $1.12 billion and generates $21.22 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Alector employs 91 workers across the globe.

What is Alector's official website?

The official website for Alector is www.alector.com.

How can I contact Alector?

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.